New Prostate Cancer Test is Ready for Commercialization Following Successful Completion of Final...

Thursday August 7, 9:12 am ET Health Discovery Corporation's New Molecular Diagnostic Test for Prostate Cancer Successfully Performs at 90% Sensitivity and 97% Specificity in Double-Blind Clinical Trial SAVANNAH, Ga.--(BUSINESS WIRE)--Health Discovery Corporation (“HDC”) (OTCBB: HDVY - News ) today announced that HDC’s new gene-based molecular diagnostic test for prostate cancer has now successfully completed it’s Phase III double-blind clinical trial and is now ready for commercialization to be used by physicians on their patients at risk of having prostate cancer. The new prostate cancer test will be performed at Clarient’s Clinical Laboratory in Aliso Viejo, CA. HDC will receive 30% royalty on each test performed. Results from Phase I, Phase II and Phase III double-blinded clinical validation studies now completed with... [read full story]